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With an estimated global prevalence of chronic kidney disease
(CKD) of 11–13%, non-invasive biomarkers of renal pathology
are desperately required to enhance early diagnosis, guide prog-
nosis and monitor response to treatment [1]. Currently, the
mainstay of renal functional monitoring remains measurement
of blood urea, serum creatinine and urinalysis, with renal biop-
sies adopted when diagnostic clarity is required.
The ideal biomarker should be non-invasive, stable and sen-
sitive, and should dynamically and specifically reflect disease
pathology so as to guide diagnosis, treatment response and
prognosis. Since their discovery in 1993, the small (20–22
nucleotides) non-coding RNAs microRNAs (miRNAs) have
been shown to have many of these qualities. MiRNAs in multi-
ple renal diseases have now been explored in renal tissue and
biofluids including blood, urine (whole, cell free and urinary
pellet), serum, plasma and perfusate from renal ex vivo perfu-
sion systems. The stable detection of miRNAs in many of these
samples is enhanced by their binding to proteins (e.g.
Argonaute and lipoproteins) and/or their encapsulation in ex-
tracellular vesicles—both of which limit their degradation by
RNases. In addition to their role as biomarkers, their ability
to negatively regulate key networks of genes by post-
transcriptional repression of mRNAs has resulted in critical
mechanistic roles being identified in development, homeostasis
and disease in multiple organs including the kidney [2]. Here,
we discuss promising non-invasive miRNA biomarkers of renal
disease in humans, highlighting the opportunities, challenges
and approaches that may enhance clinical translation of
miRNA biomarkers.
The current classical pipeline for miRNA biomarker devel-
opment is firstly high-throughput measurement of miRNAs by
small-RNA sequencing or microarray in a discovery cohort
containing the disease and sample of interest, followed by vali-
dation of key miRNAs in large and ideally prospective cohort
studies by quantitative real-time PCR (qRT-PCR). Although
miRNAs can be readily detected from a limited RNA quantity
by qRT-PCR, the output from high-throughput sequencing of-
ten requires a greater RNA quantity that can often only be reli-
ably obtained from renal tissue. However, the expression of
manymiRNAs initially profiled in renal tissue is often not faith-
fully reflected within contemporaneous biofluids. A further
technical challenge in biofluid miRNA quantification is the nor-
malization of miRNA expression levels to an exogenous and/or
endogenous control. This is particularly important when quan-
tifying miRNAs in biofluids such as urine that may drastically
vary in concentration. At present, there is little consensus in the
field on the optimal normalization approach and this may con-
tribute to incongruous results between studies [3].
With their ability to regulate and reflect disease-specific mo-
lecular pathways, a potential advantage of miRNAs is that they
may non-invasively offer diagnostic discrimination over generic
biomarkers of renal injury. For example, microRNA-148b
(miR-148b) and miR-let-7b have been shown experimentally to
regulate the O-glycosylation process of immunoglobulin A1
(IgA1) in the peripheral blood mononuclear cells of patients
with IgA nephropathy [4]. Subsequently, Serino et al. con-
ducted a large international study and demonstrated that serum
miR-148b and miR-let-7b could discriminate patients with IgA
nephropathy from both controls and patients with other forms
of glomerulonephritis [5].While a number of studies can clearly
distinguish patients with established renal disease from healthy
controls, it is the ability to both detect disease at the early stages
and discriminate the disease of interest from other renal pathol-
ogies where most diagnostic miRNA signatures require further
validation.
Another potential clinical utility of miRNAs is as predictive
markers. Within acute kidney injury (AKI), a key unmet need is
to develop a biomarker that predicts the risk of progression to
severe AKI. MiR-21 remains one of the most extensively studied
miRNAs, in the context of ischaemic AKI upregulation of uri-
nary and to a lesser extent plasma miR-21 predicted AKI pro-
gression in patients undergoing cardiac surgery [6]. In
transplantation, miR-21 was found to be upregulated in the first
urine passed of patients with delayed graft function, with the ac-
curacy of this biomarker performing best when measured as a
panel with six other miRNAs [7]. Incorporation of these
miRNA targets with clinical variables identified from logistic re-
gression in the former study importantly yielded the best pre-
dictive model.
In the context of CKD, another large study examined miR-
126 and miR-223 in the serum of 601 CKD patients (Stages 1–
5) with follow-up for 6 years [8] and found that both miRNAs
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decreased as compared with healthy controls. Although both
miRNAs tended to be lower with advancing stages of CKD,
there was no association with initial miRNA expression, and af-
ter correction for estimated glomerular filtration rate there was
no association with loss of renal function or mortality, cardio-
vascular disease and renal-related events. As the field of renal
miRNA biomarkers develops and large well-conducted studies
demonstrating non-overlapping results are reported, meta-
analyses may be required. This was the approach utilized by
Park et al., allowing them to conclude that miR-126 and the
miR-770 family in urine and blood were the most promising
markers to predict progression of diabetic nephropathy [9].
An attractive use of miRNAs would be as treatment modifi-
able biomarkers to assess response to treatment. In patients
with hypertensive nephropathy (HN), miR-103a-3p was upre-
gulated as compared with healthy controls in urine and serum.
Mechanistically, the authors demonstrated that miR-103a-3p
contributed to angiotensin II-induced HN via the SNRK/nu-
clear factor-jB/p65 regulatory axis [10]. Interestingly, patients
treated with an angiotensin-converting enzyme inhibitor or b-
blocker who responded positively with a reduction in their
albumin–creatinine ratio demonstrated a fall in miR-103a-3p,
suggesting that this miRNAmay dynamically reflect disease pa-
thology and treatment response.
A number of promising non-invasive miRNA biomarkers
have now been identified in renal disease with the potential
to augment diagnosis, guide prognosis and monitor response
to treatment—just a few are highlighted here (Figure 1).
Large prospective clinical studies with heterogenous case mix
and long follow-up are now urgently needed to determine the
accuracy and generalisability of these markers. It appears
more likely that any clinical use will require a panel of
miRNAs or miRNAs used in combination with other bio-
markers and clinical scores to improve diagnostic utility. In
addition, more meta-analyses are likely to be required due to
multiple studies with non-overlapping results.
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FIGURE 1: Opportunities and sources of non-invasive microRNA biomarkers in renal diseases. MicroRNAs highlighted in the article are sche-
matically drawn here to depict source and biomarker potential. Made using Servier Medical Art.
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